Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: A systematic review and meta‐analysis of randomized controlled trials ( CDM‐J )
Pharmacoepidemiology and Drug Safety · 2023
DOI: 10.1002/pds.5594 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2023. Verfasst von Wenbo Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Translational Science, Juntendo University Graduate School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Bone Density Conservation Agents, Osteoporosis, Postmenopausal, Fractures, Compression, Osteoporosis. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Purpose
Osteoporotic vertebral compression fracture (OVCF) is a common fragile fracture resulting from osteoporosis. We compared the efficacy and safety of romosozumab and commonly used osteoporosis drug treatments for the treatment of OVCF in postmenopausal women.
Methods
Through searching and screening five databases, we included randomized controlled trials (RCTs) published through June 18, 2021 comparing different treatments. Following the Preferred Reporting Items for Systematic Reviews statement, the main objective was to evaluate the mean difference and risk ratio of the treatment effect. The primary measures of romosozumab efficacy used in this study were vertebral, non‐vertebral, and clinical fracture events, and secondary outcomes were bone mineral density (BMD) changes at the lumbar spine, total hip, and femoral neck and the incidence of adverse events (AEs), Results Nine RCTs including 12 796 participants were included in the analysis, and romosozumab was compared with placebo, alendronate, and teriparatide in the treatment of osteoporosis in postmenopausal women. The incidence of fractures, low BMD, and AEs was analyzed. Compared with the controls, three doses of romosozumab were linked to evident advantages in the treatment of low BMD and fractures but associated with increased hypersensitivity and injection site reaction risks. Furthermore, fewer AEs were observed in the romosozumab arms (210 mg: risk ratio = 0.96, 95% confidence interval = 0.93–0.99; 140 mg: risk ratio = 0.28, 95% confidence interval = 0.08–0.98) than in the alendronate and placebo arms.
Conclusions
Our meta‐analysis revealed the evident advantages of romosozumab in the treatment of osteoporosis and low BMD in postmenopausal women and increased risks of hypersensitivity and injection site reactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Translational Science, Juntendo University Graduate School of Medicine, Tokyo, Japan.
- Medical Technology Innovation Center, Juntendo University, Tokyo, Japan.
- Department of Orthopaedic Surgery, Juntendo University Faculty of Medicine, Tokyo, Japan.
- Department of Public Health, Juntendo University Graduate School of Medicine, Tokyo, Japan.
- Department of Data Science, Juntendo University Graduate School of Medicine, Tokyo, Japan.
ORCID-Profile: Wenbo Huang, Masashi Nagao, Sen Guo
Zitieren
APA
Huang, W., Nagao, M., Yonemoto, N., Guo, S., Tanigawa, T., & Nishizaki, Y. (2023). Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: A systematic review and meta‐analysis of randomized controlled trials ( CDM‐J ). Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5594
Vancouver
Huang W, Nagao M, Yonemoto N, Guo S, Tanigawa T, Nishizaki Y. Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: A systematic review and meta‐analysis of randomized controlled trials ( CDM‐J ). Pharmacoepidemiology and Drug Safety. 2023. doi:10.1002/pds.5594
BibTeX
@article{Huang2023,
author = {Huang, Wenbo and Nagao, Masashi and Yonemoto, Naohiro and Guo, Sen and Tanigawa, Takeshi and Nishizaki, Yuji},
title = {Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: A systematic review and meta‐analysis of randomized controlled trials ( CDM‐J )},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2023},
doi = {10.1002/pds.5594}
}
EUVIMED